Failure to Monitor Residents on Anticoagulants for Adverse Effects
Summary
The facility failed to ensure that five sampled residents receiving anticoagulant therapy were monitored for signs and symptoms of adverse effects related to blood thinning medications. Residents 5 and 6 were receiving rivaroxaban, and Residents 10, 11, and 30 were receiving apixaban. For each of these residents, the record review showed that the medications were administered, but there was no documented evidence that nursing staff monitored for adverse reactions of anticoagulant therapy such as bleeding or bruising. Resident 6 had diagnoses including chronic embolism and thrombosis of unspecified deep veins of the left lower extremity and was ordered rivaroxaban for DVT prevention. Resident 30 had a history of DVT and was ordered apixaban for DVT treatment and prevention. Resident 10 had acute embolism and thrombosis of unspecified deep veins of the left lower extremity and was ordered apixaban. Resident 5 had acute embolism and thrombosis of unspecified deep veins of the left lower extremity and was ordered rivaroxaban. Resident 11 had acute embolism and thrombosis of unspecified deep veins of the right lower extremity and was ordered apixaban. In each case, the MARs showed administration of the anticoagulant, but the records did not show documented monitoring for adverse reactions during the periods reviewed. During interviews, LVN 1, LVN 3, RN 1, and the DON described that residents on anticoagulation therapy should be monitored daily for bleeding or bruising, that this monitoring should be documented in the MAR or progress notes, and that a care plan should be initiated for anticoagulation therapy. For Resident 10 and Resident 11, LVN 1 confirmed there were no physician orders for adverse reaction monitoring and no documentation of bleeding monitoring. The facility policy titled Anticoagulation - Clinical Protocol also stated staff and the physician would monitor for possible complications in individuals being anticoagulated and assess for signs or symptoms related to adverse drug reactions.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.